Trial Profile
An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Midazolam
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 18 Feb 2020 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 12 Dec 2018 Status changed from active, no longer recruiting to completed.
- 15 Jan 2018 Planned primary completion date changed from 30 Dec 2017 to 31 Mar 2018.